Targeting Autophagy to Overcome Drug Resistance in Cancer Therapy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Autophagy, a catabolic process, is activated by conditions of stress and nutrient deprivation, which occurs to maintain metabolic homeostasis by performing catabolic lysis of excessive or unnecessary proteins, and injured or aged organelles. Autophagy is regulated by various signaling pathways. Main regulators of autophagy are the PI3K-Akt-mTOR pathway, Beclin1, Bcl-2, Ras and p53. Autophagy plays dual role in cancer, shows both tumor suppressive and oncogenic activity. It is accepted that drug resistance in cancer cells can be overcome by inhibition of autophagy. Herein, we summarize autophagy as a potential target of anticancer drugs and targeting autophagy provides a promising therapeutic strategy to circumvent resistance and enhance the effect of anticancer therapies for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy in disease: a double-edged sword with therapeutic potential
Martinet, W., Agostinis, P., Vanhoecke, B., Dewaele, M., & de Meyer, G. R. Y. (2009) · Clinical Science · doi:10.1042/cs20080508 · Cited by 186
Research works printed but not linked: 18
- 10.1038/cddis.2013.422 · DOI
- 10.1016/j.bbcan.2010.07.003 · DOI · Paper page
- 10.1038/cddis.2013.350 · DOI · Paper page
- 10.1016/j.molmed.2013.04.005 · DOI · Paper page
- 10.1016/j.ceb.2009.12.007 · DOI
- 10.4155/fmc.09.155 · DOI
- 10.1242/jcs.031773 · DOI · Paper page
- 10.1155/2013/350863 · DOI
- Liu EY , RyanKM. Autophagy and cancer-issues we need to digest. J. Cell Sci.125, 1–10 (2012).
- 10.4155/fmc.13.85 · DOI
- 10.1158/1535-7163.MCT-11-0047 · DOI · Paper page
- Hippert MM , O'ToolePS, ThorburnA. Autophagy in cancer: good, bad, or both?Cancer Res.19, 66 (2006).
- 10.1016/j.pharmthera.2011.03.009 · DOI · Paper page
- 10.5732/cjc.012.10010 · DOI
- Boya P , CodognoP. Autophagy: molecular mechanisms, physiology & pathology. Tocris Biosci. Sci. Rev. Series2012, 1–16 (2012).
- 10.1016/j.canlet.2012.01.005 · DOI · Paper page
- 10.1016/j.semcancer.2013.06.008 · DOI
- 10.1016/j.semcancer.2013.05.006 · DOI
Cited by
Levy, J. M. M., Towers, C. G., & Thorburn, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.53 · Cited by 2,526
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
Zhou, J., Kang, Y., Chen, L., Wang, H., Liu, J., Zeng, S., & Yu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00343 · Cited by 479
Chen, H.-T., Liu, H., Mao, M.-J., Tan, Y., Mo, X.-Q., Meng, X.-J., Cao, M.-T., Zhong, C.-Y., Liu, Y., Shan, H., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1030-2 · Cited by 333
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Shteingauz, A., Porat, Y., Voloshin, T., Schneiderman, R. S., Munster, M., Zeevi, E., Kaynan, N., Gotlib, K., Giladi, M., Kirson, E. D., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1085-9 · Cited by 107
Metadata
- Authors
- Kumar, A., Singh, U. K., & Chaudhary, A.
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2015-08
- Volume
- 7
- Issue
- 12
- Pages
- 1535-1542
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W2116367606
- Cited by
- 136
- References
- 1
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.